

CV date	21/01/2020
---------	------------

Part A. PERSONAL INFORMATION

First and Family name:	Raúl Miguel Luque Huertas
-------------------------------	----------------------------------

A.2. Education

	University	Year
Degree (Licentiate) in Biology	University of Córdoba (UCO)	1997
Doctor in Biological Science	University of Córdoba (UCO)	2003

A.3. JCR articles, h Index, thesis supervised...: Research Sexennial: 3 (2002-2006; 2007-2011; 2011-2016); **Thesis Supervised:** 9; SCOPUS (October 2019): **JCR articles:** 155 [117 Q1 (76%), 24 D1 (16%); 128 from 2009 to date)], **H-Index:** 34, **Citations:** 3591, **Average Citation /year:** 2018-2014 (392, 404, 387, 337, 352, respectively).

Part B. CV SUMMARY: Raul M. Luque (1973), PhD, is **Associate Professor** of Cell Biology at the Department of Cell Biology of the University of Córdoba (UCO), and **Head of the -OncObesity and Metabolism- group** at the Maimonides Biomedical Research Institute of Córdoba (IMIBIC). He started his scientific career with a competitive FPU grant and continued his Postdoctoral training with a fellowship (Junta de Andalucía) and, then, as Research Assistant Professor at the University of Illinois at Chicago (USA; 2003-2007). In 2007, he was reincorporated at the UCO as **Ramón y Cajal Researcher**, establishing his own research line as PI. He has **obtained research funds (as PI) for several projects from public (MINECO/FIS/Merck-Serono/Caixa-Impulse, etc.) and private (IPSEN/Lilly/Novartis) sources and actively collaborates in national (CIBERobn/RED2018-102785-E...), and international (UE/NIH) actions**, demonstrating his leadership capacity. He has **published over 150 articles in international peer-reviewed journals over the last 15 years** (more than 50% as first or last/corresponding author), including a significant number of research papers and **invited reviews in authoritative, highly-ranked journals** (i.e. Clin Cancer Res, Mol Cancer, FASEB J, EBioMedicine, ...). His total number of citations is presently >3500, with an **H-index of 34**. In the last years, he has filed **several international patents**. He has participated as **invited speaker in numerous international meetings** (i.e. several times in the largest National and International conferences of Endocrinology and Metabolism), and **has served as member of the Editorial Board of prestigious journals of the field** (Editor in Chief, Associate Editor, etc. of JCEM, Neuroendocrinology, JOE/JME, among others). He also has acted as a **referee/member of several Spanish and International funding agencies** [i.e. ANEP, Carlos III Health Institute, Wellcome Trust (UK); Agence Nationale de la Recherche (France); Italian Ministry of Health (Italy)]. He is an **active promoter of the Spanish and European Societies of Endocrinology, Metabolism and Nutrition** (e.g., in the last 5 years he has been Member of the Executive Committee of the Spanish (SEEN, since 2019) and Andalusia (SAEDYN, since 2017) Societies of Endocrinology/Diabetes/Nutrition, and of the European ENEA European Neuroendocrine Association (ENEA), Basic Co-chair of the 20th ECE-2018, POC of 17th ENEA-Congress in 2016, etc.). Some examples for the contribution and **recognition** in these fields are the **multiple Prices and Awards** that he has received in the last years [i.e. Jens Sandahl Christiansen Award by the European Society of Endocrinology (ESE-2018) from his career in the field of Metabolism, etc.]. He has been involved in different administrative activities over the last years [e.g. Academic Director of the Master on Traslational Biomedical Research at the UCO, President of the Training Area at the IMIBIC, Coordinator of the Animal Research Service at the IMIBIC, etc.]. His teaching duties have been evaluated as excellent (95/100) by the ANECA.

Part C. RELEVANT MERITS (5-10 most relevant contributions of each section since 01/2009):

C.1. Publications (*RM Luque as corresponding author in all of them): **1)** Jiménez-Vacas JM, Herrero-Aguayo V,...**Luque RM*** (19 authors; PI in the last position). 2020. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer. EBioMedicine. [In press]. IF: 6.68 (**D1**; Medicine, Research & Experimental). **2)** Vázquez-Borrego MC, Gupta G,...**Luque RM*** (22 authors; PI in the last position). 2019. A novel SST3 agonist shows potential antitumor effects in experimental models of Nonfunctioning Pituitary Tumors. Clin Cancer Res [In

press]. IF: 8.911 (**D1**; Oncology). **3)** Gómez-Gómez E, Jiménez-Vacas JM,...**Luque RM*** (16 authors; PI in the last position). 2019. Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. *J Clin Med* 8(9). pii: E1400. IF: 5.688 (**D1**; Medicine, General & Internal). **4)** Jimenez-Vacas JM, Herrero-Aguayo V,...**Luque RM*** (15 authors; PI in the last position). 2019. Spliceosome Component SF3B1 as Novel Prognostic Biomarker and Therapeutic Target for Prostate Cancer. *Transl Res* 212:89-103. IF: 4.915 (**D1**; Medical Laboratory Technology). **5)** Vázquez-Borrego MC, Fuentes-Fayos AC,...**Luque RM*** (18 authors; PI in the last position). 2019. Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. *Cancers (Basel)* 11(10) pii: E1439. IF: 6.162 (**Q1**; Oncology). **6)** Del Rio-Moreno M, Alors-Pérez E,...**Luque RM*** (15 authors; PI in the last position). 2019. Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease. *J Clin Endocrinol Metab* 104(8):3389-3402. IF: 5.605 (**Q1**; Endocrinology and Metabolism). **7)** Vázquez-Borrego MC, L-López F,...**Luque RM*** (14 authors; PI in the last position). 2019. A new generation somatostatin-dopamine analogue exerts potent antitumoral actions on pituitary neuroendocrine tumor cells. *Neuroendocrinology* [In press]. IF: 6.804 (**D1**; Endocrinology and Metabolism). **8)** Gahete MD, Del Rio-Moreno M,...**Luque RM*** (12 authors; PI in the last position). 2018. Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study. *EBioMedicine* 37:356-365. IF: 6.68 (**D1**; Medicine, Research & Experimental). **9)** Hormaechea-Agulla D, Jiménez-Vacas JM,...**Luque RM*** (16 authors; PI in the last position). 2017. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. *FASEB J* 31(11):4682-4696. IF: 5.595 (**D1**; Biology). **10)** Hormaechea-Agulla D, Gahete MD,...**Luque RM*** (19 authors; PI in the last position). 2017. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. *Mol Can* 16(1):146. 2017. IF: 10.679 (**D1**; Oncology). **11)** Hormaechea-Agulla D, Gómez-Gómez E,...**Luque RM*** (16 authors; PI in the last position). 2016. Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker. *Cancer Lett* 383(1):125-134. IF: 6.508 (**Q1**; Oncology).

From 2009 to date, RM Luque has published 129 articles [100 Q1 (78%) and 27 D1 (21%)

[having a relevant position in 111 of these 129 (86% of the papers): 27 as first author (21%), 1 as Co-first author, 13 as second author, 14 as penultimate author, and 56 as corresponding author (43%)].

C.2. Research projects and grants [Order of description: title, founding entity, reference, amount, principal investigator (PI), entity, start and end dates-years]: **1)** Ghrelin-O-acyl-Transferase (GOAT): novel Biomarker for Screening of Prostate Cancer. Carlos III Institute of Health (ISCIII; Technological Development Projects-DTS). Ref: DTS18/00131. 88.500 €. **PI: RM Luque** (IMIBIC/UCO). 01/2019-12/2020. **2)** Novel molecular mechanisms in the pathological interaction between obesity and prostate cancer: alternative slicing and miRNAs as potential biomarkers and therapeutic targets. ISCIII (FIS project). Ref: PI16/00264. 212.052,50 €. **PI: RM Luque** (IMIBIC/UCO). 01/2017-12/2019. **3)** GOAT (Ghrelin-O-acil transferase): new biomarker for prostate cancer screening. Obra Social "La Caixa"-Caixaimpulse 2017. Ref: CI17-000015. 70.000 €. **PI: RM Luque** (IMIBIC). 07/2017-06/2019. **4)** Acquisition of scientific-technical equipment: polyvalent system of genomic analysis of last generation. Ministry of Science and Technology of Spain/European Funding for the Regional development (FEDER). Ref.: EQC2018-005254-P. Amount: 372.930 €. **PI: RM Luque**. 2018. **5)** Ghrelin-O-acil transferase (GOAT): novel biomarker for prostate cancer. Foundation for Innovation and Prospective Health in Spain-FIPSE. 30.000 €. **PI: RM Luque** (IMIBIC/UCO). 04/2017-03/2018. **6)** Therapeutic opportunities of somatostatin, ghrelin and its receptors in pituitary pathologies: identification of new molecular targets and contribution of splicing mechanisms. Excellence Program of the Junta of Andalusia Government. Ref.: CST-1406. 284.894 €. **PI: RM Luque** (UCO). 2014-18. **7)** Molecular, cellular, endocrine-metabolic and inflammatory factors involved in the pathological association between obesity and prostate cancer. ISCIII (FIS project). Ref: PI13/00651. Amount: 192.692,50 €. **PI: RM Luque** (IMIBIC/UCO). 01/2014-12/2016. **8)** Identification of novel molecular targets of the somatostatin and ghrelin regulatory systems in pituitary tumors. Merck Serono Foundation. 25.000 €. **PI: RM Luque**. 07/2013-06/2016. **9)** Volatile compounds detection system for early diagnosis of cancer. European Funding for the Regional development (FEDER). Ref.: CCB.030PM 4.873.530 €. **PI: Antonio Rodriguez [RM Luque was responsible of one work-package** (the one focused on prostate cancer)]. 2012-16. **10)** Role of cortistatin, somatostatin and ghrelin in the dysregulation of GH in obesity and fasting. Science and Innovation Ministry. Ref.: BFU2008-01136/BFI. 60.500€. **PI: RM Luque**. 2008-2010.



C.3. Contracts [description: title, company, amount, PI, affiliation entity, start and end dates-years]: **1)** Molecular and functional characterization of bladder cancer: search of novel therapies. Eli Lilly & Company. 46.200 €. **PI: RM Luque**. 2019-20. **2)** Evaluation of the effect of Dopastatin compounds on hormone secretion and cell viability in primary human pituitary adenoma cells from Cushing's patients and non-functioning pituitary adenomas. IPSEN-SCRAS S.A.S. 52.352,94 €. **PI: RM Luque**. 2016-19. **3)** Testing of the therapeutic relevance of sst3 in Non-Functioning Pituitary Adenoma (NFPA) using primary human NFPA culture cells. IPSEN-SCRAS S.A.S. 47.058 €. **PI: RM Luque**. 2016-2019. **4)** In1-ghrelin, a novel aberrantly spliced ghrelin variant, GOAT and GHSR1a and GHSR1b in neuroendocrine tumors, prostate cancer and Cushing disease: presence, function and therapeutic potential. IPSEN-SCRAS S.A.S. 120.000 €. **PI: RM Luque**. 2011-2014. **5)** Truncated sst5TMD4/5 receptors in neuroendocrine tumors, prostate cancer and Cushing disease: functional role and potential therapeutic value. IPSEN-SCRAS S.A.S. 165.000 €. **PI: RM Luque**. 2011-2014. **6)** Molecular analysis of pituitary tumors (SAEN project). NOVARTIS oncology. 146.760,4 €. **PI: RM Luque**. 2009-2012. Moreover, **RM Luque** has participated as **senior researcher in 4 additional contracts** [with: **7)** Andalusia Society of Endocrinology (2016-17); **8)** Spanish Society of Oncology (2019-20); **9)** and **10)** Spanish Group of Neuroendocrine tumors (GETNE, 2015-17 and 2019-20)].

C.4. Patents. The group of RM Luque has obtained 8 patent licenses in the last years (3 on International phases) and has participated in another one as coauthor (**Order of description: authors, reference, title, date, state/phase, institution**): **1) RM Luque**, MD Gahete, et al (11 authors). P201931147. Method for the diagnosis and prognosis of the development of brain tumors in an individual. 20/12/2019. National Phase. UCO/Andalusia Health System (SAS). **2) RM Luque**, MD Gahete, et al (9 authors). P201930104. Method for the diagnosis and prognosis of the development of prostate cancer. 08/02/2019. National Phase. UCO/Andalusia Health System (SAS). **3) RM Luque**, JP Castaño, et al (9 authors). P201831039. Method for the diagnosis, prognosis and treatment of neuroendocrine tumors. 25/10/2018. National Phase. UCO/SAS. **4) R López, RM Luque**, et al (11 authors). P201930123. Method of obtaining useful data for the diagnosis, stratification and/or follow-up of patients with rheumatoid arthritis. National Phase. 14/09/2018. UCO/SAS. **5) MD Gahete, RM Luque**, et al (14 authors). P201831095. Method for the prediction and prognostic of the development of type 2 diabetes mellitus. 13/11/2018. National Phase. UCO/SAS. **6) MD Gahete, RM Luque**, et al (5 authors). PCT/ES2018/070361. Peptides derived from the truncated somatostatin receptor 5 sst5TMD4 as biomarkers and therapeutic tools in tumoral pathologies. 16/12/2016. International Phase. UCO/SAS. **7) RM Luque**, JP Castaño, et al (11 authors). PCT/ES2017/070797. Non-invasive diagnostic method of cancer. 16/12/2016. International Phase/PCT. UCO/SAS. **8) RM Luque**, JP Castaño, et al (10 authors). PCT/ES2016/070844. Ghrelin-O-acyl transferase (GOAT) and their uses. International Phase/PCT. 27/11/2015. UCO/SAS. **9) RM Luque**, JP Castaño, et al (8 authors). P201030905. Ghrelin variant and its uses. 8/01/2013. National Phase. UCO/SAS/Univ. of Chicago.

C.5. Management of Scientific/Academic activities (last 5 years): **1) Director** of the “Translational Biomedical Research” Master at the University of Cordoba (since 2016). **2) President** of the formation/training area of the Maimonides Biomedical Research Institute of Córdoba (IMIBIC; since 2018). **3) Coordinator** of the Neuroendocrinology Group of the Andalusia Society of Endocrinology/Diabetes and Nutrition (SAEDYN, since 2018). **4) Member** of the Ethics Committee for Experimentation in Biomedicine (Univ. of Córdoba; 2014-2019). **5) Coordinator** of the Experimental Animal Service -SAE at the IMIBIC (2011-2015); **6) First Spanish Representative** of the Young Investigators Committee from the European Association of Neuroendocrinology (Enea).

C.6. Member of editorial committees (last 5 years): **RM Luque** is/has been member of the editorial board of several prestigious international journals (included in the JCR) as: **Chief Editor** (Frontiers in Endocrinology: Systems and Translational Endocrinology section: 2014-2019), **Senior Editor** (Journal of Endocrinology and J Mol Endocrinol: 2019-to date), **Associated Editor** [PLOS one (2011-to date) and Int J Mol Sci (2019-to date)], or as **member of the expert panel** (Neuroendocrinology, J Clin Endocrinol Metab-JCEM, J Endocrinol, J Mol Endocrinol, J Endocrinol Invest, etc.).

C.7. Member/reviewer of scientific evaluation panels (last 5 years): **RM Luque** is or has been: **1)** Member of the evaluation panel of the Technical Commission of Health Research Projects from the Carlos III Health Institute (ISCIII; FIS-projects: Endocrine, Digestive and Surgery Diseases, 2014-2017); **2)** Supervisor of the panel of the interest conflicts of the Health and Families Counseling of the Andalusia Government (2018-2019); and, **3)** Referee/Member of several Spanish and International funding agencies [i.e. ANEP, AECC and ISCIII (Spain), Wellcome Trust (UK); Agence Nationale de



la Recherche (France); Italian Ministry of Health, Argentina Research and technologic Agency etc.], as well as of different biopharmaceutical foundations (e.g. AztraZeneca, etc.).

C.8. Member of International committees/ Organization of International Congresses (last 5 years): **1)** Member of the Congress Committee of the European Society of Endocrinology (ESE) for the European Congresses in 2021 and 2022 (ECE; Largest European Endocrinology meeting). **2)** Chair of the Spanish Society of Endocrinology Congress (SEEN; Seville, 2020), **3)** Member of the Expert Panel for the ESE Focus Area on Pituitary and Neuroendocrinology (since 2018). **4)** Co-Chair of the 20th ECE organized by ESE (Barcelona, 2018), **5)** Member of Executive Committees of the SEEN (since 2019), SAEDYN (since 2017) and ENEA (since 2017). **6)** Member of the POC of the 17th Congress of the ENEA (Largest NeuroEndocrinology meeting in Europe; 2016). **7)** Member of the organizing committee of the congress "New Frontiers in Obesity Research" organized by the ESE / CIBERobn (Córdoba, 2016).

C.9. Invitation to National/International meetings: In the last 5 years, **RM Luque** has been invited several times to present the results of his team (Conferences/symposiums) in the largest conferences of Endocrinology/Diabetes/Obesity at the Regional and National level [e.g. Spanish-SEEN, Andalusia-SAEDYN, and Valencian-SVEDyN Societies of Endocrinology and Nutrition: SAEDYN (2018, 2012, 2020), SEEN (2012, 2015, 2019), SVEDyN (2017), and the Spanish Society of Obesity (SEEDO: 2018)], European level [e.g. European Society of Endocrinology (ESE: 2019, 2013, 2009) and European Neuroendocrine Association (ENEA: 2010, 2020): largest European conferences of Endocrinology and Neuroendocrinology], and at International level [e.g. The International Congress of Endocrinology (2020), The Endocrine Societies of North-American (2017; largest conference worldwide), The Latin American Society (2020), of Argentina (2020), of Brazil (CBEM: 2018), of Portugal (2015), of Egypt (2012), etc.]. Moreover, he has been invited at numerous scientific seminars in different Spanish and international institutions, including the several universities [e.g. Cardiff (UK), Illinois at Chicago (USA), Santiago de Compostela, Elche-Valencia, Seville (Spain), Leuven (Belgium), among others] and research centers [e.g. IBIS and CABIMER (Seville), Ramón y Cajal Institute (IRYCIS, Madrid), Paulo Niemeyer Brain Institute (Rio de Janeiro, Brazil), among others].

C.10. Relevant awards (last 5 years): **1)** European "Jens Sandahl Christiansen" Award by the European Society of Endocrinology (ESE2018) for his outstanding career in the Metabolism field. **2)** IMIBIC Award "Enrique Aguilar Benitez de Lugo" to the most relevant publication (2017); **3)** Prize to the Research Career of the group "Hormones and Cancer" (RM Luque was the Co-PI of the group) awarded by the Foundation of the Spanish Society of Endocrinology and Nutrition (FSEEN2016). **4)** Numerous awards and distinctions for the best research work and best posters or oral communications in several Societies and National/International Congresses of Endocrinology (Spanish, American and European Societies, European Neuroendocrine Association, Pituitary Society, etc.).

C.11. Supervision of researchers/Students: From 01/01/2009 to date, RM Luque has supervised 10 doctoral theses [4 with Extraordinary Prize of Doctorate, 9 with International mention, 5 with compendium of publications, being one of them defended 3 days after the deadline of this call: on 24/01/20]. Moreover, he is currently supervising 10 doctoral theses (all of them in the Doctoral Program of Biomedicine). Additionally, RM Luque has supervised 26 TFM (Master's Thesis) in the "Translational Biomedical Research" and "Biotechnology" Masters at the University of Cordoba (UCO), being some of them awarded as the best TFM of the University (2010-11, 2015-16, etc.).